OVID has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OVID has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Ovid Therapeutics's accounts receivables for the quarter that ended in Dec. 2024 was $0.00 Mil.
Accounts receivable can be measured by Days Sales Outstanding. Ovid Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2024 was 0.00.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Ovid Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $0.41.
The historical data trend for Ovid Therapeutics's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovid Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Accounts Receivable | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Ovid Therapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Accounts Receivable | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Ovid Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0.076 | * | 91 |
= | 0.00 |
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Ovid Therapeutics's accounts receivable are only considered to be worth 75% of book value:
Ovid Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:
Net-Net Working Capital Per Share | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (53.075 | + | 0.75 * 0 | + | 0.5 * 0 | - | 23.941 |
- | 0 | - | 0) | / | 71.010 | ||
= | 0.41 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Thank you for viewing the detailed overview of Ovid Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey A Rona | officer: Chief Business Officer | 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Jeremy M Levin | director, 10 percent owner, officer: CEO | |
Jason Tardio | officer: Chief Commercial Officer | 1460 BROADWAY, NEW YORK NY 10036 |
Takeda Pharmaceuticals U.s.a., Inc. | 10 percent owner | ONE TAKEDA PARKWAY, DEERFIELD IL 60015 |
Kevin Joseph Fitzgerald | director | C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036 |
Amit Rakhit | officer: CMO and PMO | C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036 |
Robert Michael Poole | director | 200 W. HIGHLAND DR., #303, SEATTLE WA 98119 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
Thomas Michael Perone | officer: SVP, General Counsel | 1460 BROADWAY, NEW YORK NY 10036 |
Karen Bernstein | director | C/O VITAE PHARMACEUTICLS, INC., 502 WEST OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034 |
Millennium Pharmaceuticals Inc | 10 percent owner | 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Douglas E Williams | director | C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799 |
Ana Ward | officer: SVP and General Counsel | C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036 |
Barbara Gayle Duncan | director | C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013 |
Timothy Daly | officer: VP, Finance & Corp. Controller | 20 KINGSBRIDGE ROAD, PISCATAWAY NJ 08854 |
From GuruFocus
By Marketwired • 09-26-2024
By Marketwired • 09-11-2024
By Business Wire • 08-02-2024
By Marketwired • 07-26-2024
By Marketwired • 11-12-2024
By PRNewswire • 08-02-2024
By Marketwired • 08-08-2024
By Marketwired • 07-12-2024
By Marketwired • 02-27-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.